The story
In June 2012 Jennifer Doudna of the University of California, Berkeley, and Emmanuelle Charpentier, then working in Sweden, published a paper in Science with their colleagues showing that a bacterial protein called Cas9 could be programmed to cut DNA at almost any spot a scientist chose. The protein is guided by a short piece of RNA, a molecule similar to DNA, whose letters match the target. Change the guide's sequence and you change where Cas9 cuts. Their team also simplified the system by fusing two natural RNA pieces into a single guide, making it easy to design. Gene editing, once slow, expensive and imprecise, suddenly became something almost any lab could do.
The tool came from studying how bacteria fight viruses. In 1987 Japanese scientists noticed strange repeating DNA sequences in bacteria, later named CRISPR, short for 'clustered regularly interspaced short palindromic repeats'. In the 2000s researchers, including Francisco Mojica in Spain, realized that the spacers between the repeats matched viral DNA: bacteria were storing snippets of past invaders as a kind of genetic memory, then using CRISPR-associated (Cas) proteins to recognize and slice those viruses if they returned. Charpentier discovered a key RNA in the system in 2011 and teamed up with Doudna, a specialist in RNA structure. The work rested on decades of recombinant DNA and PCR methods for handling and copying genes.
Once Cas9 cuts both strands of DNA, the cell rushes to repair the break. Its quick repair often scrambles a few letters, switching the gene off, while a slower route can copy in a new sequence supplied by the scientist. In early 2013, teams led by Feng Zhang at the Broad Institute and George Church at Harvard showed that the system worked in human cells, sparking a long patent battle between Berkeley and the Broad.
Labs worldwide adopted CRISPR within months to study genes in plants, animals and human cells. It also raised alarms. In 2018 the Chinese scientist He Jiankui announced the birth of twin girls whose embryos he had edited, drawing worldwide condemnation and a prison sentence. Doudna and Charpentier won the 2020 Nobel Prize in Chemistry, and in 2023 regulators approved the first CRISPR-based therapy, for sickle cell disease.
Why it mattered
- The first CRISPR therapy, Casgevy, was approved in 2023 to treat sickle cell disease and beta thalassemia.
- CRISPR-edited foods reached shops, beginning with a tomato sold in Japan in 2021.
- Biological research sped up dramatically, since scientists could switch off any gene to learn what it does.
- Ethical debates over editing human embryos led to calls for international limits on heritable changes.
Sources
- CRISPR Timeline Broad Institute
- The Nobel Prize in Chemistry 2020, Popular information NobelPrize.org
- History of CRISPR-Cas from Encounter with a Mysterious Repeated Sequence to Genome Editing Technology Journal of Bacteriology
- FDA approves world's first CRISPR-based medicine for sickle cell STAT
- Chinese Researcher Who Created Gene-Edited Babies Sentenced To 3 Years In Prison NPR
Drafted by AI (Claude) from the sources above and checked against them by AI; no historian has reviewed this page. Spot a mistake? Suggest a correction. How pages are made
Community notes
Loading notes…